Teva | pharmaphorum

Skip to main content

Monday 27 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Teva

News

AstraZeneca (AZ)

AZ hopes to boost respiratory pipeline with Pieris deal

AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.

News

Neuron_in_tissue_culture

FDA approves Teva's Huntington's Disease drug

First treatment approved for Huntington's Disease in almost a decade.

News

TevaCanada2

Teva files orphan blockbuster hope in tardive dyskinesia

SD-809 will be vital for Teva if approved.

Views & Analysis

Revlimid1

Orphan drugs will fuel pharma's future - and a pricing pushb...

Evaluate predicts sales could approach $8bn if approved.

News

Mylan settles narcolepsy drug pay-for-delay case

Payment ends decade of litigation.

News

TevaCanada2

Teva's CEO Vigodman steps down

Firm searches for new leader, chairman takes over on interim basis.

Load more results

Editor's Picks

Novo's Wegovy pill cleared for weight loss in EU

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

Bayer's Kerendia on course for NHS use in heart failure

MSD gets first FDA okay for oral PCSK9 cholesterol drug

GSK abandons cough drug added in $2bn Bellus deal

News

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company